Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | GALR3 | O60755 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.44 |
| ▸ | GLRB | P48167 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4128042 | 0.85 | MEN1 (0.43) | MEN1KMT2ASMN1; SMN2HTTGALR3 | |
| SCHEMBL4128218 | 0.84 | KMT2A (0.42) | MEN1KMT2ASMN1; SMN2HTTGALR3 | |
| SCHEMBL4128995 | 0.83 | THRA (0.38) | MEN1KMT2ASMN1; SMN2HTTTDP1 | |
| SCHEMBL4114244 | 0.78 | KMT2A (0.47) | MEN1KMT2ASMN1; SMN2HTTGALR3 | |
| SCHEMBL4122654 | 0.77 | MEN1 (0.46) | MEN1KMT2ASMN1; SMN2HTTGALR3 | |
| SCHEMBL11764473 | 0.74 | GLRA3 (0.57) | MEN1KMT2ASMN1; SMN2HTTGALR3 | |
| SCHEMBL5053296 | 0.74 | BCL2L1 (0.53) | MEN1KMT2ASMN1; SMN2HTTGALR3 | |
| SCHEMBL4122596 | 0.73 | GLRA3 (0.49) | MEN1KMT2ASMN1; SMN2HTTGALR3 | |
| SCHEMBL4113993 | 0.73 | TP53 (0.49) | MEN1KMT2ASMN1; SMN2HTTGALR3 | |
| SCHEMBL4113997 | 0.72 | MEN1 (0.53) | MEN1KMT2ASMN1; SMN2HTTGALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192190-A1 | Benzoic Acid Derivatives that are Modulators or Agonists of GlyR | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | claimed |
| EP-1890993-A2 | BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR ANTAGONISTS OF GLYR | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | claimed |
| WO-2006121390-A2 | BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR AGONISTS OF GLYR | ASTRAZENECA AB (SE) | 2006-11-16 | — | — | WO | claimed |
| US-20090192190-A1 | Benzoic Acid Derivatives that are Modulators or Agonists of GlyR | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| EP-1890993-A2 | BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR ANTAGONISTS OF GLYR | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006121390-A2 | BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR AGONISTS OF GLYR | ASTRAZENECA AB (SE) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192190-A1 | Benzoic Acid Derivatives that are Modulators or Agonists of GlyR | GLRA1, GLRB, GPBAR1 | MEN1 2512/4885KMT2A 2465/4885SMN1; SMN2 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.